814
Participants
Start Date
July 28, 2020
Primary Completion Date
November 12, 2021
Study Completion Date
January 14, 2022
mavrilimumab
anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
Placebo
matching placebo
TASK Eden, George
Tiervlei Trial Center, Cape Town
University of Cape Town - Lung Institute, Cape Town
IATROS International, Bloemfontein
Essalud - Hospital de Emergencias Grau, Lima Cercado
Clinica Providencia, San Miguel
Hospital Nacional Cayetano Heredia, San Martín de Porres
Bryn Mawr Hospital, Bryn Mawr
University of Cincinnati, Cincinnati
Allina Health System, Minneapolis
Affinity Health, Chicago
Mercy Clinic Hospitalists, Springfield
Tulane University School of Medicine, New Orleans
University of Texas Health Sciences, Houston
UCLA Medical Center, Los Angeles
SHARP Health Care, San Diego
Clinica Las Condes, Santiago
Hospital Clinico Universidad de Chile, Santiago
Hospital Cardio Pulmonar, Salvador
Hospital Luxemburgo - Associação Mário Penna, Belo Horizonte
CPCLIN - Centro de Pesquisas Clínicas, Natal
Hospital Bruno Born, Lajeado
UPECLIN - Unidade de Pesquisa Clínica, Botucatu
IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto
Hospital Adventista de Belem, Belém
IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará, Fortaleza
Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José
Hospital Alemão Oswaldo Cruz, São Paulo
Hospital Nacional Alberto Sabogal Sologuren, Bellavista
Into Research - Little Company of Mary Medical Center, Pretoria
Limpopo Clinical Research Initiative, Rustenburg
Lead Sponsor
Collaborators (1)
Kiniksa Pharmaceuticals, Ltd.
INDUSTRY
Kiniksa Pharmaceuticals International, plc
INDUSTRY